Hot Pursuit     27-Feb-25
Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility
Dr Reddy's Laboratories has announced that it has received establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility (CTO-2) in Bollaram, Hyderabad.
The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed that the inspection is now closed.

According to a filing with the exchange dated 19 November 2024, the inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issued a Form 483 with seven observations during the inspection, which the company has committed to addressing within the stipulated timeline.

Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The pharma company reported 2.4% increase in consolidated net profit to Rs 1,413.70 crore in Q3 FY25 compared with Rs 1,380.90 crore in Q3 FY24. Net sales jumped 15.9% to Rs 8,358.60 crore in Q3 FY25 compared with Rs 7,214.80 crore in Q3 FY24.

The scrip rose 0.20% to Rs 1,128.80 on the BSE.

Previous News
  Dr Reddys announces cessation of subsidiary in Louisiana
 ( Corporate News - 24-Mar-25   13:48 )
  Dr Reddys Laboratories to conduct board meeting
 ( Corporate News - 22-Mar-25   11:01 )
  Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US
 ( Corporate News - 13-Mar-25   18:46 )
  Dr Reddys Laboratories allots 11,250 equity shares under ESOS
 ( Corporate News - 06-Mar-25   19:16 )
  Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy’s Labs
 ( Hot Pursuit - 04-Mar-25   15:35 )
  Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's
 ( Corporate News - 04-Mar-25   14:23 )
  Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility
 ( Hot Pursuit - 27-Feb-25   09:57 )
  Dr Reddys Laboratories allots 20,155 equity shares under ESOS
 ( Corporate News - 14-Feb-25   18:24 )
  Dr Reddys Laboratories Ltd up for third consecutive session
 ( Hot Pursuit - 06-Feb-25   13:06 )
  Dr Reddys Laboratories Ltd drops for fifth straight session
 ( Hot Pursuit - 29-Jan-25   13:35 )
  Dr Reddys Laboratories
 ( Results - Analysis 24-Jan-25   10:17 )
Other Stories
  Kamat Hotels Q4 PAT surges 412% YoY to Rs 11 cr
  26-Apr-25   16:21
  Bank of Maharashtra Q4 PAT climbs 23% YoY to Rs 1,493 crore
  26-Apr-25   15:34
  Oracle Financial Services Software Q4 PAT up 19% QoQ
  26-Apr-25   14:28
  Force Motors Q4 PAT surges 210% YoY to Rs 435 cr; declares dividend of Rs 40/sh
  26-Apr-25   14:02
  L&T Finance Q4 PAT rises 15% YoY to Rs 636 crore
  26-Apr-25   13:31
  RBL Bank PAT drops 81% YoY to Rs 69 crore in Q4 FY25; provisions zoom by 90% YoY
  26-Apr-25   12:12
  Tejas Networks reports dismal Q4 outcome
  26-Apr-25   11:54
  Zydus Life gets 6 observations from USFDA for API plant
  26-Apr-25   11:02
  RIL Q4 PAT rises 6.4% YoY
  26-Apr-25   10:05
  Tata Technologies Q4 PAT climbs 12% QoQ to Rs 189 cr
  25-Apr-25   17:34
Back Top